





FIGURE 1

A



B




FIGURE 2




FIGURE 3






FIGURE 3 (contd.)



WO 2022/175413





FIGURE 4

FIGURE 5

PCT/EP2022/054004




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9





FIGURE 9 (contd.)




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21

c)

% improvement in EC50	
No mAb	100%
D1.3 IgG1	109%
1252_P01_C08 IgG1	337%
1245_P02_G04 IgG	383%
1245_P01_E07 IgG	159%

D)

EC50s		
	$\gamma\delta$ T-cell	T:E ratio
No mAb	8729	0.11
D1.3 IgG1	8019	0.12
1252_P01_C08 IgG1	2594	0.39
1245_P02_G04 IgG	2278	0.44
1245_P01_E07 IgG	5485	0.18

FIGURE 21 (contd.)


D

	5 hrs	12 hrs	24 hrs
No mAb	100%	100%	100%
D1.3	114%	99%	112%
D1.3 IgG LAGA	106%	96%	113%
D1.3 FS1-67	149%	143%	147%
Cetuximab	121%	110%	126%
C08- LAGA	99%	84%	101%
E07- LAGA	115%	117%	127%
G04- LAGA	141%	128%	163%
C08 FS1-67	467%	424%	371%
E07 FS1-67	303%	292%	259%
G04 FS1-67	254%	232%	212%


H

	5 hrs	12 hrs	24 hrs
No mAb	100%	100%	100%
D1.3	114%	99%	112%
D1.3 IgG LAGA	106%	96%	113%
D1.3 LAGA Cetuximab	132%	123%	118%
Cetuximab	121%	110%	126%
C08- LAGA	99%	84%	101%
E07- LAGA	115%	117%	127%
G04- LAGA	141%	128%	163%
C08 LAGA Cetuximab	334%	313%	245%
E07 LAGA Cetuximab	208%	216%	187%
G04 LAGA Cetuximab	197%	210%	158%


C




G




B



F



A



E




FIGURE 22

I

	EC50s		
	$\gamma\delta$ T-cell	T:E ratio	% improvement
No mAb	4102	0.24	100%
D1.3 IgG1	3651	0.27	112%
D1.3 IgG LAGA	3640	0.27	113%
E07-LAGA	3229	0.31	127%
D1.3 FS1-67	2794	0.36	147%
Cetuximab	3246	0.31	126%
E07 FS1-67	1581	0.63	259%

J




FIGURE 22 (contd.)

A)

		EC50s	
	$\gamma\delta$ T-cell	T:E ratio	% improvement
RSV IgG	1988	1.99	100%
	G04	2.13	93%
	E07	1.78	112%
D1.3 VHVL	1143	1.14	174%
G04 VHVL	470	0.47	423%
E07 VHVL	828	0.83	240%

FIGURE 23

B)




FIGURE 23 cont.




Figure 24A




Figure 24B




Figure 24C




Figure 25A

Figure 25B




Figure 25C




Figure 26A




Figure 26B





Figure 26C


D (i)

huV δ 1cynoV δ 1


ADT1-4




ADT1-4 (S74L)



ADT1-4-2



ADT1-4-2 (L74S)



D (ii)

Antibody	huV δ 1 [KD]	cynoV δ 1 [KD]
ADT1-4	47nM	397nM
ADT1-4 (S74L)	3.5nM	77nM
ADT1-4-2	0.34nM	2.6nM
ADT1-4-2 (L74S)	4nM	61nM

Figure 26 cont.




Figure 27A




Figure 27B




Figure 27C




Figure 28




Figure 29




Figure 30A




Figure 30B




Figure 30C

Human KD




Figure 31A

Cyno KD




Figure 31B




Figure 31C

Clones: ADT1-4-derived Analyte: human VD1

A




Figure 32A




Figure 32B

Clone	Avg KD (M)	Fold-change
ADT1-4	1.49E-07	1.00
ADT1-4-2	1.90E-10	784.21
ADT1-4-19	1.77E-10	841.81
ADT1-4-21	4.74E-10	314.35
ADT1-4-31	4.42E-10	337.49
ADT1-4-53	5.07E-10	294.18
ADT1-4-86	7.16E-10	208.25
ADT1-4-112	5.65E-10	263.95
ADT1-4-143	4.24E-10	351.42

Figure 32C




Figure 32E

Clone	Avg KD (M)	Fold-change
ADT1-7	3.81E-08	1.00
ADT1-7-3	3.78E-09	10.07
ADT1-7-20	4.99E-09	7.63
ADT1-7-61	1.04E-09	36.62

Figure 32D




Figure 32F

A

Clone	Avg KD (M)
ADT1-4	No binding
ADT1-4-2	1.92E-09
ADT1-4-19	2.25E-09
ADT1-4-21	4.38E-09
ADT1-4-31	6.45E-09
ADT1-4-53	4.01E-09
ADT1-4-86	9.22E-09
ADT1-4-112	8.27E-09
ADT1-4-143	7.61E-09

B




Figure 33

A




Figure 34A




Figure 34B

	ATS006			TS164		
	IC50	% improvement in	IC50	IC50	% improvement in	IC50
ADT1-7	>100	0.00	0.00	225.6	0.00	0.00
ADT1-7-3	5.153	N/A	N/A	0.9517	23604.95	
ADT1-7-20	37.22	N/A	N/A	2.684	8305.37	
ADT1-7-61	93.01	N/A	N/A	195.7	15.28	

mAb	ATS006			TS164		
	IC50	% improvement in	IC50	IC50	% improvement in	IC50
ADT1-4	107.7	0.00	575.9	0.00		
ADT1-4-2	2.164	4876.89	1.703	33716.79		
ADT1-4-19	2.375	4434.74	2.456	23348.70		
ADT1-4-21	2.536	4146.85	1.675	34282.09		
ADT1-4-31	3.33	3134.23	2.63	21797.34		
ADT1-4-53	2.228	4733.93	2.456	23348.70		
ADT1-4-86	5.357	1910.45	2.34	24511.11		
ADT1-4-112	2.621	4009.12	2.436	23541.22		
ADT1-4-143	2.819	3720.50	3.066	18683.43		

C




Figure 34C


mAb	IC50 (nM)							
	Donor 1 (ATS006)	Donor 2 (TS164)	HEK293T	Raji	CD8 (PBMC)	CD4 (PBMC)	CD56 (PBMC)	CD19 (PBMC) CD14 (PBMC)
ADT1-4	107.7	575.9	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-2	2.164	1.703	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-19	2.375	2.456	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-21	2.536	1.675	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-31	3.33	2.63	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-53	2.228	2.456	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-86	5.357	2.34	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-112	2.621	2.436	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-4-143	2.819	3.066	No binding	No binding	No binding	No binding	No binding	No binding

mAb	IC50 (nM)							
	Donor 1 (ATS006)	Donor 2 (TS164)	HEK293T	Raji	CD8 (PBMC)	CD4 (PBMC)	CD56 (PBMC)	CD19 (PBMC) CD14 (PBMC)
ADT1-7	>100	225.6	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-7-3	5.153	0.9517	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-7-20	37.22	2.684	No binding	No binding	No binding	No binding	No binding	No binding
ADT1-7-61	93.01	195.7	No binding	No binding	No binding	No binding	No binding	No binding

mAb	IC50 (nM)			
	Donor 1 (ATS006)	CD8 (PBMC)	CD4 (PBMC)	CD56 (PBMC) CD19 (PBMC) CD14 (PBMC)
OKT3	2.889	0.252	0.1906	No binding
RSV (IgG control)	No binding	No binding	No binding	No binding

Figure 34D

A



B




Figure 35




Figure 35 cont.

G

	IC50	% improvement in IC50
ADT1-4	38.28	100
OKT3	19.43	197
ADT1-4-2	0.31	12348
ADT1-4-31	0.24	15630
ADT1-4-21	0.27	14372
ADT1-4-86	0.31	12472
ADT1-4-143	0.31	12219
ADT1-4-19	0.37	10420
ADT1-4-53	0.25	15090
ADT1-4-112	0.30	12964
ADT1-4-1	0.36	6185
ADT1-4-6	0.48	4648
ADT1-4-138	8.38	266

	IC50	Fold improvement in IC50
ADT1-4	38.28	1
OKT3	19.43	2
ADT1-4-1	0.36	62
ADT1-4-2	0.31	123
ADT1-4-6	0.48	46
ADT1-4-19	0.37	104
ADT1-4-21	0.27	144
ADT1-4-31	0.24	156
ADT1-4-53	0.25	151
ADT1-4-86	0.31	125
ADT1-4-112	0.30	130
ADT1-4-138	8.38	3
ADT1-4-143	0.31	122

	IC50	% improvement in IC50
ADT1-7	22.42	100
OKT3	19.43	115
ADT1-7-3	0.16	13968
ADT1-7-20	0.16	13697
ADT1-7-61	6.26	358

	IC50	Fold improvement in IC50
ADT1-7	22.42	1
OKT3	19.43	1
ADT1-7-3	0.16	140
ADT1-7-20	0.16	137
ADT1-7-61	6.26	4

Figure 35 cont

F





Figure 36

C




E

WO 2022/175413

	% increase in CD107a positive cells
ADT1-4-2	24.705
ADT1-7-3	26.7

F




PCT/EP2022/054004

Condition	mAb	% maximum increase in CD107a positive cells
GD	ADT1-4-2	-3.73
GD	ADT1-7-3	-1.28
GD + THP-1	ADT1-4-2	19.53
GD + THP-1	ADT1-7-3	22.3

Figures 36 cont.

A



B





Figure 37


ADT1-7-3 GD Cells alone



WO 2022/175413

	% increase in CD25 expression
ADT1-4-2	170.1
ADT1-7-3	220.9

E



F

Condition	mAb	% maximum increase in CD25 expression
GD	ADT1-4-2	-15.23
GD + THP-1	ADT1-4-2	116.8
GD	ADT1-7-3	3.84
GD + THP-1	ADT1-7-3	162.2

PCT/EP2022/054004

Figure 37 cont.






Figure 38





Figure 38 cont.



MEAN IC50s in THP-1 killing assay




Figure 39
61 / 122

D

Clone ID	THP-1 killing assay EC50 [pM] (average of ≥3 donors)	Standard deviation	Fold improvement	% improvement over parent
OKT3 _(anti-CD3)	3.53	2.40		
ADT1-4	121.47	136.80	1.0	100%
ADT1-4-1	3.00	2.87	40.5	4049%
ADT1-4-2	6.33	3.67	19.2	1918%
ADT1-4-6	0.93	0.07	130.1	13014%
ADT1-4-19	8.33	6.13	14.6	1458%
ADT1-4-21	6.13	2.93	19.8	1980%
ADT1-4-31	10.93	4.73	11.1	1111%
ADT1-4-53	7.40	3.13	16.4	1641%
ADT1-4-86	7.60	2.87	16.0	1598%
ADT1-4-112	6.47	3.53	18.8	1878%
ADT1-6-138	2.53	0.73	47.9	4795%
ADT1-4-143	13.07	9.27	9.3	930%
ADT1-7	65.20	54.80	1.0	100%
ADT1-7-20	1.87	0.53	34.9	3493%
ADT1-7-3	1.33	0.87	48.9	4890%
ADT1-7-61	3.60	3.60	18.1	1811%

Figure 39 cont.




Figure 40




Figure 41




Figure 42




Figure 43





Figure 43 cont.




Figure 43 cont.
68 / 122




Figure 44

ADT1-4-105 2499_01_D07
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPQITFFGQTRLEIK

ADT1-4-107 2499_01_F07
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPQITFFGQTRLEIK

ADT1-4-110 2499_02_A02
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPQVTFGAGTRLEIK

ADT1-4-112 2499_02_B04
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSQPQVTFGQTRLEIK

ADT1-4-117 2499_02_F12
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPRVTFGQTRLEIK

ADT1-4-19 2501_01_H01
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPKVTFGQTRLEIK

ADT1-4-21 2501_02_A05
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPWVTFGQTRLEIK

ADT1-4-31 2501_02_G09
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPPVTFGQTRLEIK

ADT1-4-139 2502_01_C07
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQGYSTPQITFFGQTRLEIK

ADT1-4-4 2502_01_E01
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPWVTFGQTRLEIK

ADT1-4-143 2502_01_E05
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTHQVTFGQTRLVIK

ADT1-4-53 2505_02_E12
DIQMTQSPFALSASVGDRVTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISSLQPDDEFATYYCQQXYSTPQITFFGQTRLEIK

Figure 45

ADT1-4-173 2505_02_G11
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSAPOVTFGQGRLEIK

ADT1-4-2 2506_01_B10
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSAPOVTFGQGRLEIK

ADT1-4-8 2506_01_B11
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSAPOVTFGQGRLEIK

ADT1-4-82 2506_02_B09
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSTPQITFGQGRLEIK

ADT1-4-83 2506_02_B10
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSEPOVTFGQGRLEIK

ADT1-4-3 2506_02_C01
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSTPEVTFGQGRLEIK

ADT1-4-84 2506_02_C02
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSDPOVTFGQGRLEIK

ADT1-4-86 2506_02_C12
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSEPOVTFGQGRLEIK

ADT1-4-95 2506_02_H04
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSTPQVTFGSGTRLEIK

ADT1-4-1 2501_01_C09
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSTPIVTFGQGRLEIK

ADT1-4-6 2506_1_B06
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPLRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYKTPQVTFGQGRLEIK

ADT1-4-138 2502_01_B03
DIQMTQSPALASVGDRTTITCRASQDINDWLAWYQHKGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISLQPDDEFATYYCQOKYSTDQVTFGQGRLEIK

Figure 45 cont.

ADT1-4-105 2499_01_D07
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-107 2499_01_F07
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVVMGGTLTVTVSS

ADT1-4-110 2499_02_A02
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVEYVDVVMGGTLTVTVSS

ADT1-4-112 2499_02_B04
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-117 2499_02_F12
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-19 2501_01_H01
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-21 2501_02_A05
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-31 2501_02_G09
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-139 2502_01_C07
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVVMGGTLTVTVSS

ADT1-4-4 2502_01_E01
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVVMGGTLTVTVSS

ADT1-4-143 2502_01_E05
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSAANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVVMGGTLTVTVSS

ADT1-4-53 2505_02_E12
EVQLQSGPGGLVKPQTLSLTCAISGDSVSSKSVANNWIRQSPRGLEWLGRTVYRSKWSTDYAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWADYVDVVMGGTLTVTVSS

ADT1-4-173 2505_02_g11
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWAGYDDVWGQGTLLTVSS

ADT1-4-2 2506_01_B10
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGVDVWGQGTLLTVSS

ADT1-4-8 2506_01_B11
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVWGQGTLLTVSS

ADT1-4-82 2506_02_B09
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARSWVGVDVWGQGTLLTVSS

ADT1-4-83 2506_02_B10
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARSWVGVDVWGQGTLLTVSS

ADT1-4-3 2506_02_C01
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWADYVDVWGQGTLLTVSS

ADT1-4-84 2506_02_C02
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVWGQGTLLTVSS

ADT1-4-86 2506_02_C12
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSV~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWLGNDVVDVWGQGTLLTVSS

ADT1-4-95 2506_02_H04
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVWGQGTLLTVSS

ADT1-4-1 2501_01_C09
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWVGADVWGQGTLLTVSS

ADT1-4-6 2506_1_B06
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWAGYDDVWGQGTLLTVSS

ADT1-4-138 2502_01_B03
EVQLQQSGPGLVKPQSQTLSLTCAISGDSVSSKSA~~AA~~NNWIQSPSRGLEWLGRTYYRSKWS~~TD~~YAAASVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARTWADYVDVWGQGTLLTVSS

Figure 46 cont.

ADT1-7-10 2503_1_C12
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQTASTLLTFFGRGTKVEIK

ADT1-7-15 2503_1_F01
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSADTLLTFFGRGTKVEIK

ADT1-7-17 2503_1_G05
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSGSELLTFFGRGTKVEIK

ADT1-7-18 2503_1_G06
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSASELLTFFGRGTKVEIK

ADT1-7-19 2503_1_G10
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSASELLTFFGRGTKVEIK

ADT1-7-20 2503_1_H02
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSASELLTFFGRGTKVEIK

ADT1-7-22 2503_2_A02
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSYSGLDTFFGRGTKVEIK

ADT1-7-23 2503_2_A07
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSASELLTFFGRGTKVEIK

ADT1-7-42 2503_2_H06
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSYSGLDTFFGRGTKVEIK

ADT1-7-3 2504_1_A01
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSYSGLDTFFGRGTKVEIK

ADT1-7-61 2504_1_F02
DIQMTQSPSSLSASVGDRVTIACRAGQSICTYLNWYQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSASELLTFFGRGTKVEIK

Figure 47

ADT1-7-10 2503_1_C12
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDDYNDAFDIWGQGTLLTVYSS

ADT1-7-15 2503_1_F01
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDDYNDAFDIWGQGTLLTVYSS

ADT1-7-17 2503_1_G05
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARIDYEDAFDIWGQGTLLTVYSS

ADT1-7-18 2503_1_G06
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARVSYDDAFDIWGQGTLLTVYSS

ADT1-7-19 2503_1_G10
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARIDYEDAFDIWGQGTLLTVYSS

ADT1-7-20 2503_1_H02
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARVDYQEAFDIWGQGTLLTVYSS

ADT1-7-22 2503_2_A02
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDDYNDAFDIWGQGTLLTVYSS

ADT1-7-23 2503_2_A07
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARVDYNEAFDIWGQGTLLTVYSS

ADT1-7-42 2503_2_H06
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDDYEDAFDIWGQGTLLTVYSS


ADT1-7-3 2504_1_A01
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARVSYAEAFDIWGQGTLLTVYSS

ADT1-7-61 2504_1_F02
EVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMSWIROAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDDYDDAFDIWGQGTLLTVYSS

Figure 48


FIG 49

Anti-V δ 1 mAb




Human V δ 1

Anti-V δ 1/ CD19 bispecific



Cyno V δ 1



Cyno VD1 binding





FIG 50A






FIG 50 cont.




FIG 50 cont.









FIG 50 cont.





FIG 51

FIG 51 cont.






FIG 51 cont.




FIG 51 cont.





FIG 52A






FIG 53A




FIG 53B






FIG 54



D



E




FIG 54 cont.




FIG 55




FIG 55 cont.

E




FIG 55 cont.




FIG 56






FIG 56 cont.

D



E




FIG 56 cont.




FIG 56 cont.

A





FIG 57

B

IgG binding to HeLa cells



C

IgG binding to $\gamma\delta$ T-cells





FIG 57 cont.

D



E






FIG 57 cont.

F



G



H




FIG 57 cont.

A





FIG 58

B



C




FIG 58 cont

D






FIG 58 cont

E



F



G




FIG 58 cont




FIG 59



B**C**

FIG 59 cont.

D






FIG 59 cont.

E



F



G




FIG 59 cont.

A




FIG 60
110 / 122




B**C**

FIG 60 cont.

D



E





FIG 60 cont.

F



G




FIG 60 cont.

A





FIG 61

B



C




FIG 61 cont.

D






FIG 61 cont.

E



F



G




FIG 61 cont.




FIG 62




FIG 63




FIG 63 (cont)




FIG 64




FIG 65